The MosaiQ COVID-19 Antibody Microarray tests for both IgM and IgG antibodies to SARS-CoV-2, the virus that causes COVID-19, offering one of the earliest antibody detection tests available. Independent and internal studies have confirmed best-in-class performance with 100% sensitivity and 99.8% specificity. It can detect seroconversion as early as 24 hours post PCR and detects antibodies as early as 7 days post PCR. The innovative technology that allowed Quotient to create the MosaiQ COVID-19 Antibody Microarray is powered by the proprietary MosaiQ Reaction that delivers fast, accurate results every 24 seconds on the MosaiQ system – a multiplexing, multimodal solution for central laboratories. The best-in-class MosaiQ COVID-19 Antibody Microarray is CE marked, has received the U.S. FDA Emergency Use Authorization (EUA).
